Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Is Regeneron's Stock in Trouble After This FDA Rejection?
Is Regeneron's Stock in Trouble After This FDA Rejection?
Is Regeneron's Stock in Trouble After This FDA Rejection?
Submitted by
admin
on July 6, 2023 - 10:15am
Source:
Motley Fool
News Tags:
Regeneron
Eylea
FDA
Headline:
Is Regeneron's Stock in Trouble After This FDA Rejection?
snippet:
The Food and Drug Administration didn't approve Regeneron's higher-dose version of Eylea.
Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or efficacy.
Do Not Allow Advertisers to Use My Personal information
